205 related articles for article (PubMed ID: 11389040)
1. Effects of mixed hematopoietic chimerism in a mouse model of bone marrow transplantation for sickle cell anemia.
Iannone R; Luznik L; Engstrom LW; Tennessee SL; Askin FB; Casella JF; Kickler TS; Goodman SN; Hawkins AL; Griffin CA; Noffsinger L; Fuchs EJ
Blood; 2001 Jun; 97(12):3960-5. PubMed ID: 11389040
[TBL] [Abstract][Full Text] [Related]
2. Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease.
Kean LS; Manci EA; Perry J; Balkan C; Coley S; Holtzclaw D; Adams AB; Larsen CP; Hsu LL; Archer DR
Blood; 2003 Dec; 102(13):4582-93. PubMed ID: 12933586
[TBL] [Abstract][Full Text] [Related]
3. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia.
Walters MC; Patience M; Leisenring W; Rogers ZR; Aquino VM; Buchanan GR; Roberts IA; Yeager AM; Hsu L; Adamkiewicz T; Kurtzberg J; Vichinsky E; Storer B; Storb R; Sullivan KM;
Biol Blood Marrow Transplant; 2001; 7(12):665-73. PubMed ID: 11787529
[TBL] [Abstract][Full Text] [Related]
4. A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation.
Kean LS; Durham MM; Adams AB; Hsu LL; Perry JR; Dillehay D; Pearson TC; Waller EK; Larsen CP; Archer DR
Blood; 2002 Mar; 99(5):1840-9. PubMed ID: 11861303
[TBL] [Abstract][Full Text] [Related]
5. Adoptive immunotherapy to increase the level of donor hematopoietic chimerism after nonmyeloablative marrow transplantation for severe canine hereditary hemolytic anemia.
Takatu A; Nash RA; Zaucha JM; Little MT; Georges GE; Sale GE; Zellmer E; Kuhr CS; Lothrop CD; Storb R
Biol Blood Marrow Transplant; 2003 Nov; 9(11):674-82. PubMed ID: 14652850
[TBL] [Abstract][Full Text] [Related]
6. Relationship between Mixed Donor-Recipient Chimerism and Disease Recurrence after Hematopoietic Cell Transplantation for Sickle Cell Disease.
Abraham A; Hsieh M; Eapen M; Fitzhugh C; Carreras J; Keesler D; Guilcher G; Kamani N; Walters MC; Boelens JJ; Tisdale J; Shenoy S; ;
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2178-2183. PubMed ID: 28882446
[TBL] [Abstract][Full Text] [Related]
7. Mixed chimerism following in utero hematopoietic stem cell transplantation in murine models of hemoglobinopathy.
Hayashi S; Abdulmalik O; Peranteau WH; Ashizuka S; Campagnoli C; Chen Q; Horiuchi K; Asakura T; Flake AW
Exp Hematol; 2003 Feb; 31(2):176-84. PubMed ID: 12591283
[TBL] [Abstract][Full Text] [Related]
8. At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT.
Fitzhugh CD; Cordes S; Taylor T; Coles W; Roskom K; Link M; Hsieh MM; Tisdale JF
Blood; 2017 Oct; 130(17):1946-1948. PubMed ID: 28887325
[TBL] [Abstract][Full Text] [Related]
9. Photochemical treatment of donor lymphocytes inhibited their ability to facilitate donor engraftment or increase donor chimerism after nonmyeloablative conditioning or establishment of mixed chimerism.
Johnson BD; Taylor PA; Stankowski MC; Talib S; Hearst JE; Blazar BR
Biol Blood Marrow Transplant; 2002; 8(11):581-7. PubMed ID: 12463476
[TBL] [Abstract][Full Text] [Related]
10. Extensive multilineage analysis in patients with mixed chimerism after allogeneic transplantation for sickle cell disease: insight into hematopoiesis and engraftment thresholds for gene therapy.
Magnani A; Pondarré C; Bouazza N; Magalon J; Miccio A; Six E; Roudaut C; Arnaud C; Kamdem A; Touzot F; Gabrion A; Magrin E; Couzin C; Fusaro M; André I; Vernant JP; Gluckman E; Bernaudin F; Bories D; Cavazzana M
Haematologica; 2020 May; 105(5):1240-1247. PubMed ID: 31537695
[TBL] [Abstract][Full Text] [Related]
11. Immune Reconstitution Kinetics following Intentionally Induced Mixed Chimerism by Nonmyeloablative Transplantation.
Kim N; Lee H; Shin J; Nam YS; Im KI; Lim JY; Lee ES; Kang YN; Park SH; Cho SG
PLoS One; 2015; 10(5):e0126318. PubMed ID: 25961559
[TBL] [Abstract][Full Text] [Related]
12. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
[TBL] [Abstract][Full Text] [Related]
13. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia.
Iannone R; Casella JF; Fuchs EJ; Chen AR; Jones RJ; Woolfrey A; Amylon M; Sullivan KM; Storb RF; Walters MC
Biol Blood Marrow Transplant; 2003 Aug; 9(8):519-28. PubMed ID: 12931121
[TBL] [Abstract][Full Text] [Related]
14. Bone Marrow Transplantation after Nonmyeloablative Treosulfan Conditioning Is Curative in a Murine Model of Sickle Cell Disease.
Devadasan D; Sun CW; Westin ER; Wu LC; Pawlik KM; Townes TM; Goldman FD
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1554-1562. PubMed ID: 29684562
[TBL] [Abstract][Full Text] [Related]
15. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers.
Colson YL; Wren SM; Schuchert MJ; Patrene KD; Johnson PC; Boggs SS; Ildstad ST
J Immunol; 1995 Nov; 155(9):4179-88. PubMed ID: 7594573
[TBL] [Abstract][Full Text] [Related]
16. Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France.
Bernaudin F; Dalle JH; Bories D; de Latour RP; Robin M; Bertrand Y; Pondarre C; Vannier JP; Neven B; Kuentz M; Maury S; Lutz P; Paillard C; Yakouben K; Thuret I; Galambrun C; Dhedin N; Jubert C; Rohrlich P; Bay JO; Suarez F; Raus N; Vernant JP; Gluckman E; Poirot C; Socié G;
Haematologica; 2020 Jan; 105(1):91-101. PubMed ID: 31097628
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of chimerism after allogeneic bone marrow transplantation with unmanipulated marrow by use of DNA polymorphisms.
Suttorp M; Schmitz N; Dreger P; Schaub J; Löffler H
Leukemia; 1993 May; 7(5):679-87. PubMed ID: 8097800
[TBL] [Abstract][Full Text] [Related]
18. Mixed donor chimerism following stem cell transplantation for sickle cell disease.
Shah NC; Rangarajan HG; Ngwube A; Shenoy S
Curr Opin Hematol; 2023 Nov; 30(6):187-193. PubMed ID: 37694765
[TBL] [Abstract][Full Text] [Related]
19. High-level allogeneic chimerism achieved by prenatal tolerance induction and postnatal nonmyeloablative bone marrow transplantation.
Peranteau WH; Hayashi S; Hsieh M; Shaaban AF; Flake AW
Blood; 2002 Sep; 100(6):2225-34. PubMed ID: 12200389
[TBL] [Abstract][Full Text] [Related]
20. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies.
Spitzer TR; McAfee S; Sackstein R; Colby C; Toh HC; Multani P; Saidman S; Weyouth DW; Preffer F; Poliquin C; Foley A; Cox B; Andrews D; Sachs DH; Sykes M
Biol Blood Marrow Transplant; 2000; 6(3A):309-20. PubMed ID: 10905768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
